Treatment

Zejula 100 mg hard capsules clinical trials

3 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic exploratory (Phase II)
OPAL Master Protocol: A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments and/or Combinations of Treatments in Participants with Ovarian Cancer (OPAL) (PR-3000-02-005/213357) Cohort C: Open-label Phase 2, Randomized, Controlled Multicenter Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants with Homologous Recombination- Deficient Stage III/IV Ovarian Cancer
This study looks at new ways to treat advanced ovarian cancer before surgery. It compares a drug called niraparib with standard chemotherapy. Researchers want to see if the new approach is safer and works better for certain types of ovarian cancer.
For: Ovarian Neoplasms
Spain
Ongoing, recruitingTherapeutic use (Phase IV)
NIRAPK : Study of the relationships between pharmacokinetic properties (PK) and hematological toxicity of niraparib in ovarian cancer
This study looks at how a cancer drug called niraparib (Zejula) affects patients with ovarian cancer. Researchers want to understand why some patients experience side effects like changes in their blood or kidney problems, by studying how the body handles the drug.
For: Patients with high-grade serous epithelial ovarian · tubal or primary peritoneal cancers
France
AuthorisedTherapeutic exploratory (Phase II)
A Phase II, Randomized, Trial of Niraparib Versus Best Supportive Careas Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion Of First-line Platinum-containing Chemotherapy (MEET URO 12)
This study is looking at a new medicine called Zejula for people with a type of bladder cancer (urothelial cancer) that has spread. It's for patients who have already had chemotherapy and whose cancer hasn't gotten worse. We want to see if Zejula can help keep the cancer from growing for longer.
For: urothelial cancer
Italy

NIRAPK : Study of the relationships between pharmacokinetic properties (PK) and hematological toxicity of niraparib in ovarian cancer

A Phase II, Randomized, Trial of Niraparib Versus Best Supportive Careas Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion Of First-line Platinum-containing Chemotherapy (MEET URO 12)